« Return to News | Ethics/Regulatory

FDA says drug approvals highest in two decades

Friday, July 8, 2011 02:15 PM

Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, testified before the U.S. House Energy and Commerce's health subcommittee that first-cycle drug approvals are at a 20-year high, and more than two-thirds of new treatments are being cleared within the time frames given to new drug applications.

The director also noted the agency approved 20 compounds so far this year, one less than the total for all of 2010, and that the FDA meets more than 90% of drug-review deadlines, according to FirstWord.  

At the hearing, Woodcock fielded questions regarding the FDA’s regulatory process, which some lawmakers suggested "has become less transparent and [has] increased the time it takes for products to reach those who need them." However, she proposed that challenges being faced by the biotechnology and pharmaceutical industries are related to high failure rates of drugs in development rather than the FDA's regulations.

OncoMed Pharmaceuticals CEO Paul Hastings, who also testified at the hearing, said "regulatory uncertainty, longer drug development timelines and an increasing regulatory and Congressional focus on risk instead of reward in pharmaceutical innovation deters limited partners from investing in biotech venture capital firms and subsequently deters venture capitalists from investing in biotechnology discovery companies."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.